| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 10.05.
| CURIS INC - 10-Q, Quarterly Report | | 3 | SEC Filings |
| 09.05.
| Curis is Among the Companies in the Biotechnology Industry With the Highest Sales Growth | | 10 | SmarTrend |
| 07.05.
| Curis (CRIS) Says Roche Submitted Erivedge for Registration in Australia, Receives $4M Milestone Payment | | 4 | StreetInsider.com |
| 04.04.
| Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907 | | 61 | AFX News |
| WASHINGTON (dpa-AFX) - Curis Inc. (CRIS) announced the presentation of data
in a poster session at the American Association for Cancer Research or AACR
Annual Meeting 2012 in Chicago, Illinois.The...
Mehr lesen zu:
Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907 | |
| 16.02.
| Debiopharm und Curis geben den Beginn von Phase Ib der Erweiterungsstudie des HSP90-Hemmers Debio 0932 bekannt | | 76 | news aktuell-CH |
| Lausanne, Schweiz/Lexington (Massachusetts), USA (ots) - Curis, Inc. (NASDAQ: CRIS), ein in der Medikamentenentwicklung tätiges Unternehmen mit Schwerpunkt auf proprietär zielgerichtete Arzneimittel...
Mehr lesen zu:
Debiopharm und Curis geben den Beginn von Phase Ib der Erweiterungsstudie des HSP90-Hemmers Debio 0932 bekannt | |
| 16.02.
| Curis (CRIS), Debiopharm Report Initiation of HSP90 Phase Ib | | - | StreetInsider.com |
| 16.02.
| Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932 | | 38 | PR Newswire |
| LAUSANNE, Switzerland and LEXINGTON, Massachusetts, February 16, 2012 /PRNewswire/ --
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for...
Mehr lesen zu:
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932 | |
| 08.02.
| Curis Swings To Q4 Profit | | 45 | AFX News |
| WASHINGTON (dpa-AFX) - Curis, Inc. (CRIS) reported net income for the fourth
quarter of $6.1 million or $0.07 per share, compared to a net loss of $5.6
million or $0.07 per share for the...
Mehr lesen zu:
Curis Swings To Q4 Profit | |
| 30.01.
| Curis (CRIS) Reports the FDA Approval of Erivedge; Will Get $10M Milestone | | 7 | StreetInsider.com |
| 30.01.
| Curis (CRIS) Shares Jump as Genentech's Erivedge Approved by FDA for Basal Cell Carcinoma | | 5 | StreetInsider.com |
| 22.12.
| Curis (CRIS) Reports Submission of MAA for Vismodegib to EMA | | 7 | StreetInsider.com |
| 22.12.
| Curis Announces Collaborator Roche's Submission of Marketing Authorization Application for Vismodegib in Advanced Basal Cell Carcinoma | | 104 | Business Wire |
| Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced...
Mehr lesen zu:
Curis Announces Collaborator Roche's Submission of Marketing Authorization Application for Vismodegib in Advanced Basal Cell Carcinoma | |
| 06.12.
| Curis to Present at the Oppenheimer & Company's 22nd Annual Healthcare Conference | | 21 | Business Wire |
| Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced...
Mehr lesen zu:
Curis to Present at the Oppenheimer & Company's 22nd Annual Healthcare Conference | |
| 30.11.
| Curis (CRIS) Announces Partnership with The Leukemia & Lymphoma Society to Develop CUDC-907 for Lymphoma and Multiple Myeloma | | 1 | StreetInsider.com |
| 30.11.
| Curis Announces Agreement with The Leukemia & Lymphoma Society to Develop CUDC-907 for Lymphoma and Multiple Myeloma | | 17 | Business Wire |
| - Agreement provides for up to $4 million in funding by LLS for
Curis' continuing evaluation of its first-in-class PI3 kinase and HDAC
inhibitor –
...
Mehr lesen zu:
Curis Announces Agreement with The Leukemia & Lymphoma Society to Develop CUDC-907 for Lymphoma and Multiple Myeloma | |
